Sandoz Group AG (SWX: SDZ)
Market Cap | 16.29B |
Revenue (ttm) | 9.09B |
Net Income (ttm) | -7.19M |
Shares Out | 438.72M |
EPS (ttm) | -0.02 |
PE Ratio | n/a |
Forward PE | 13.06 |
Dividend | 0.45 (1.21%) |
Ex-Dividend Date | n/a |
Volume | 2,358,848 |
Open | 36.75 |
Previous Close | 37.05 |
Day's Range | 36.18 - 37.17 |
52-Week Range | 25.33 - 41.16 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 5, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
In 2023, Sandoz Group AG's revenue was $9.98 billion, an increase of 7.23% compared to the previous year's $9.31 billion. Earnings were $77.00 million, a decrease of -90.92%.
Financial numbers in USD Financial StatementsNews
Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion
Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Sandoz Charts Path to Swift Generic Ozempic Launch in Canada
Sandoz Group AG plans to use the Canadian market as a trial balloon for generic Ozempic, challenging Novo Nordisk A/S with a copycat version as soon as 2026.
Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S.
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking a significant additio...
Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP
Glenmark Pharmaceuticals Inc., USA, headquartered in Mahwah, New Jersey, has announced the launch of Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution). This product is a bioequivale...
Sandoz Group: Moving To A 'Hold' After A 50% Move
Sandoz Group's stock has surged nearly 50% since my last article, driven by strong performance in the generics and biosimilars sector. Read more here.
Axsome Therapeutics reaches agreement to dismiss patent litigation with Sandoz
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars ...
Sandoz Group AG (SDZNY) (Q2 2024) Earnings Call Transcript Highlights: Strong Biosimilars Growth and Raised Sales Guidance
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Half Year 2024 Sandoz Group AG Earnings Call Transcript
Sandoz Group Non-GAAP EPS of $1.12, revenue of $5B
Sandoz Group AG (SDZNY) Q2 2024 Earnings Call Transcript
Sandoz Group AG 2024 Q2 - Results - Earnings Call Presentation
Won't see major development in weight loss indication drugs in EU or U.S. until 2030, Sandoz CEO says
Richard Saynor, CEO of Sandoz, discusses the firm's half-year results and shares his outlook for innovation in the weight loss drug market.
Generic weight-loss drugs? They’re coming — eventually, executive says
Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.